CONTENTS:
- Who is responsible for the public's health? The role of the alcohol industry in the WHO global strategy to reduce the harmful use of alcohol [Editorial]. Babor T., Hall W., Humphreys K., Miller P., Petry N., West R., p. 2045-2047.
- Unrecorded alcohol: significant neglected challenges [Editorial]. Thamarangsi T., p. 2048-2050.
- Alcohol - a universal preventive agent? A critical analysis [For debate]. Fekjaer H.O., p. 2051-2057.
- The role of the comparison group in epidemiology and general limitations. Rehm J., p. 2058-2059.
- Alcohol as a panacea: Limitations of observational studies. Andréasson S., p. 2059-2060.
- Response to commentaries. Fekjaer H.O., p. 2060-2061.
- Gambling experiences, problems and policy in India: a historical analysis. Benegal V., p. 2062-2067.
- Influence of affective manipulations on cigarette craving: a meta-analysis. Heckman B.W., Kovacs M.A., Marquinez N.S., Meltzer L.R., Tsambarlis M.E., Drobes D.J., et al., p. 2068-2078.
- Commentary on Heckman et al. (2013): Negative affect increases craving - Questions about the relationship of affect, craving and smoking. Shiffman S., p. 2079-2080.
- Availability of convenience stores and adolescent alcohol use in Taiwan: a multi-level analysis of national surveys. Wang S.-H., Lin I.C., Chen C.-Y., Chen D.-R., Chan T.-C., Chen W.J., p. 2081-2088.
- Commentary on Wang et al. (2013): Time to test the mechanisms of alcohol outlet density effects. Livingston M., p. 2089-2090.
- Predicting persistency of DSM-5 alcohol use disorder and examining drinking patterns of recently remitted individuals: a prospective general population study. Tuithof M., ten Have M., van den Brink W., Vollebergh W., de Graaf R., p. 2091-2099.
- Commentary on Tuithof et al. (2013): Implications of the DSM-5 revision for the analysis of persistence/remission of alcohol use disorder. Dawson D.A., p. 2100-2101.
- Drinking context-specific associations between intimate partner violence and frequency and volume of alcohol consumption. Mair C., Cunradi C.B., Gruenewald P.J., Todd M., Remer L., p. 2102-2111.
- The impact of a national alcohol policy on deaths due to transport accidents in Russia. Pridemore W.A., Chamlin M.B., Kaylen M.T., Andreev E., p. 2112-2118.
- Cumulative and recent psychiatric symptoms as predictors of substance use onset: does timing matter? Cerdá M., Bordelois P.M., Keyes K.M., Galea S., Koenen K.C., Pardini D., p. 2119-2128.
- Childhood conduct disorder trajectories, prior risk factors and cannabis use at age 16: birth cohort study. Heron J., Barker E.D., Joinson C., Lewis G., Hickman M., Munafò M., et al., p. 2129-2138.
- Commentary on Heron et al. (2013): Findings on associations between conduct problem trajectories, early risk factors and adolescent cannabis use - how do they fit with existing theories? Hemphill S.A., p. 2139-2140.
- Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone. Rosenthal R.N., Ling W., Casadonte P., Vocci F., Bailey G.L., Kampman K., et al., p. 2141-2149.
- Commentary on Rosenthal et al. (2013): Buprenorphine implant - new hopes, old questions. Basu D., p. 2150-2151.
- Engagement with the criminal justice system among opioid-dependent people: a retrospective cohort study. Degenhardt L., Gisev N., Trevena J., Larney S., Kimber J., Burns L., et al., p. 2152-2165.
- Cost-effectiveness analysis of Recovery Management Checkups (RMC) for adults with chronic substance use disorders: evidence from a 4-year randomized trial. McCollister K.E., French M.T., Freitas D.M., Dennis M.L., Scott C.K., Funk R.R., p. 2166-2174.
- Deviant smooth pursuit in preschool children exposed prenatally to methadone or buprenorphine and tobacco affects integrative visuomotor capabilities. Melinder A., Konijnenberg C., Sarfi M., p. 2175-2182.
- An increase in primary care prescriptions of stop-smoking medication as a result of health insurance coverage in the Netherlands: population based study. Verbiest M.E.A., Chavannes N.H., Crone M.R., Nielen M.M.J., Segaar D., Korevaar J.C., et al., p. 2183-2192.
- Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice. Stapleton J., West R., Hajek P., Wheeler J., Vangeli E., Abdi Z., et al., p. 2193-2201.
- Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. David S.P., Strong D.R., Leventhal A.M., Lancaster M.A., McGeary J.E., Munafò M.R., et al., p. 2202-2211.
- ‘No-one actually goes to a shop and buys them do they?’: attitudes and behaviours regarding illicit tobacco in a multiply disadvantaged community in England. Stead M., Jones L., Docherty G., Gough B., Antoniak M., McNeill A., p. 2212-2219.
- Risk factor-based interventions or population-based smoking policy initiatives in tobacco smoking prevention? A reply to Najman (2013) concerning commentary on Lindström et al. (2013). Lindström M., p. 2220-2220.
- Increased population drinking is not always associated with increased number of drink driving convictions. Gjerde H., Christophersen A.S., Normann P.T., Mørland J., p. 2221-2223.